Sidley represented Attralus, Inc., a clinical stage biopharmaceutical company focused on developing therapies to improve the lives of patients with systemic amyloidosis, in the close of its US$116 million Series B preferred stock financing. The financing was led by Logos Capital and included Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), and Vivo Capital. Founding investor, venBio Partners, also participated in the financing.
The Sidley deal team was led by Mehdi Khodadad and included Mark Castiglia, Anthony Friedman, Ryan Hicks, Max Chaffetz, and Jin Choi (paralegal) with support from Eric Kauffman (Employment), Stacy Crosnicker (Employee Benefits and Executive Compensation), Torrey Cope (Food, Drug, and Medical Device Regulatory), as well as Dusan Clark and Kim Littlejohn (paralegal) (both Technology and IP Transactions).